$TTOO
T2 Biosystems, Inc. Stock $ttoo

$ttoo Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000095017024094135 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$1.985M	$1.952M
YoY Change	34.85%	-0.61%
Cost Of Revenue	$4.101M	$2.693M
YoY Change	4.48%	-44.69%
Gross Profit	-$2.116M	-$741.0K
YoY Change	-13.74%	-74.49%
Gross Profit Margin	-106.6%	-37.96%
Selling, General & Admin	$5.378M	$5.473M
YoY Change	-10.07%	-13.07%
% of Gross Profit
Research & Development	$2.667M	$3.361M
YoY Change	0.15%	-12.7%
% of Gross Profit
Depreciation & Amortization	$59.00K	$62.00K
YoY Change	-77.74%	-76.78%
% of Gross Profit
Operating Expenses	$8.045M	$8.834M
YoY Change	-6.92%	-12.93%
Operating Profit	-$10.16M	-$9.575M
YoY Change	-25.33%	-26.63%
Interest Expense	-$293.0K	$760.0K
YoY Change	-126.18%	-50.68%
% of Operating Profit
Other Income/Expense, Net	$44.00K	$32.00K
YoY Change	-102.42%	-99.52%
Pretax Income	-$10.12M	-$8.783M
YoY Change	-34.41%	38.38%
Income Tax
% Of Pretax Income
Net Earnings	-$10.12M	-$8.783M
YoY Change	-34.41%	38.38%
Net Earnings / Revenue	-509.67%	-449.95%
Basic Earnings Per Share	-$0.57	-$0.64
Diluted Earnings Per Share	-$0.57	-$0.62
COMMON SHARES
Basic Shares Outstanding	17.48M	8.793M
Diluted Shares Outstanding	17.89M	14.10M

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.083M	$4.246M
YoY Change	-91.43%	-73.6%
Cash & Equivalents	$2.083M	$4.246M
Short-Term Investments
Other Short-Term Assets	$1.845M	$2.283M
YoY Change	-41.19%	8.71%
Inventory	$3.825M	$5.169M
Prepaid Expenses
Receivables	$2.033M	$1.297M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$9.786M	$13.00M
YoY Change	-70.23%	-45.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.477M	$8.173M
YoY Change	-27.67%	78.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$551.0K	$552.0K
YoY Change	747.69%	1026.53%
Total Long-Term Assets	$8.296M	$8.725M
YoY Change	-20.27%	-34.2%
TOTAL ASSETS
Total Short-Term Assets	$9.786M	$13.00M
Total Long-Term Assets	$8.296M	$8.725M
Total Assets	$18.08M	$21.72M
YoY Change	-58.22%	-41.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.210M	$1.686M
YoY Change	286.95%	-24.53%
Accrued Expenses	$4.627M	$7.278M
YoY Change	-6.6%	-30.02%
Deferred Revenue	$233.0K	$237.0K
YoY Change	-15.58%	-10.57%
Short-Term Debt	$11.92M	$11.79M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.44M	$23.40M
YoY Change	-55.94%	-64.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.357M	$5.820M
YoY Change	-24.14%	-22.37%
Total Long-Term Liabilities	$5.357M	$5.820M
YoY Change	-24.14%	-22.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.44M	$23.40M
Total Long-Term Liabilities	$5.357M	$5.820M
Total Liabilities	$29.79M	$29.22M
YoY Change	-52.35%	-60.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$616.9M	-$606.8M
YoY Change	7.47%	8.65%
Common Stock	$605.2M	$600.9M
YoY Change	9.1%	15.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$11.70M	-$7.497M
YoY Change
Total Liabilities & Shareholders Equity	$18.08M	$21.72M
YoY Change	-58.22%	-41.5%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$10.12M	-$8.783M
YoY Change	-34.41%	38.38%
Depreciation, Depletion And Amortization	$59.00K	$62.00K
YoY Change	-77.74%	-76.78%
Cash From Operating Activities	-$6.252M	-$9.241M
YoY Change	-53.31%	-25.4%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.089M	7.279M
YoY Change	-81.1%	-60.41%
NET CHANGE
Cash From Operating Activities	-6.252M	-9.241M
Cash From Investing Activities		0.000
Cash From Financing Activities	4.089M	7.279M
Net Change In Cash	-2.163M	-1.962M
YoY Change	-126.28%	-132.88%
FREE CASH FLOW
Cash From Operating Activities	-$6.252M	-$9.241M
Capital Expenditures		$0.00
Free Cash Flow		-$9.241M
YoY Change		-25.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001492674
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2024Q1	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesCurrent
CY2024Q2	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesCurrent
CY2024Q2	us-gaap	Notes Payable Related Party Type Extensible Enumeration NotesPayableRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Notes Payable Related Party Type Extensible Enumeration NotesPayableRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36571
	dei	Entity Registrant Name EntityRegistrantName	T2 Biosystems, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4827488
	dei	Entity Address Address Line1 EntityAddressAddressLine1	101 Hartwell Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	Lexington
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02421
	dei	City Area Code CityAreaCode	781
	dei	Local Phone Number LocalPhoneNumber	761-4646
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	TTOO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17479954
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4246000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15689000
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1297000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1420000
CY2024Q2	us-gaap	Inventory Net InventoryNet	5169000
CY2023Q4	us-gaap	Inventory Net InventoryNet	4819000
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2284000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3261000
CY2024Q2	us-gaap	Assets Current AssetsCurrent	12996000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	25189000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1517000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1658000
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6656000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7395000
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	551000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	551000
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4000
CY2024Q2	us-gaap	Assets Assets	21721000
CY2023Q4	us-gaap	Assets Assets	34797000
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1686000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1527000
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4276000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4905000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1687000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1616000
CY2024Q2	ttoo	Derivative Warrant Liabilities Current DerivativeWarrantLiabilitiesCurrent	387000
CY2023Q4	ttoo	Derivative Warrant Liabilities Current DerivativeWarrantLiabilitiesCurrent	235000
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	237000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	224000
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21799000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	56152000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5746000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6598000
CY2024Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	74000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	83000
CY2024Q2	us-gaap	Liabilities Liabilities	27619000
CY2023Q4	us-gaap	Liabilities Liabilities	62833000
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	93297
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	93297
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17394249
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17394249
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4058381
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4058381
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	17000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	600878000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	556256000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-606793000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-584296000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-5898000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-28036000
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21721000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34797000
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1952000
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1964000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4013000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4042000
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3361000
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3850000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7082000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8321000
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5473000
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6296000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12211000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13595000
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	11527000
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	15015000
	us-gaap	Costs And Expenses CostsAndExpenses	26188000
	us-gaap	Costs And Expenses CostsAndExpenses	30780000
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9575000
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13051000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22175000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26738000
CY2024Q2	ttoo	Interest Expense To Related Party InterestExpenseToRelatedParty	478000
CY2023Q2	ttoo	Interest Expense To Related Party InterestExpenseToRelatedParty	1541000
	ttoo	Interest Expense To Related Party InterestExpenseToRelatedParty	1657000
	ttoo	Interest Expense To Related Party InterestExpenseToRelatedParty	3063000
CY2024Q2	ttoo	Change In Fair Value Of Derivative Related To Term Loan With Related Party ChangeInFairValueOfDerivativeRelatedToTermLoanWithRelatedParty	1238000
CY2023Q2	ttoo	Change In Fair Value Of Derivative Related To Term Loan With Related Party ChangeInFairValueOfDerivativeRelatedToTermLoanWithRelatedParty	1022000
	ttoo	Change In Fair Value Of Derivative Related To Term Loan With Related Party ChangeInFairValueOfDerivativeRelatedToTermLoanWithRelatedParty	1130000
	ttoo	Change In Fair Value Of Derivative Related To Term Loan With Related Party ChangeInFairValueOfDerivativeRelatedToTermLoanWithRelatedParty	252000
CY2024Q2	ttoo	Change In Fair Value Of Derivative Warrant Liability ChangeInFairValueOfDerivativeWarrantLiability	-180000
CY2023Q2	ttoo	Change In Fair Value Of Derivative Warrant Liability ChangeInFairValueOfDerivativeWarrantLiability	7192000
	ttoo	Change In Fair Value Of Derivative Warrant Liability ChangeInFairValueOfDerivativeWarrantLiability	-152000
	ttoo	Change In Fair Value Of Derivative Warrant Liability ChangeInFairValueOfDerivativeWarrantLiability	5888000
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	32000
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	357000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-651000
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	612000
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6704000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-322000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2426000
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-8963000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6347000
	us-gaap	Net Income Loss NetIncomeLoss	-22497000
	us-gaap	Net Income Loss NetIncomeLoss	-24312000
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.84
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.84
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-51.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-51.23
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14095348
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14095348
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	809168
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	809168
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9595079
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9595079
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	474609
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	474609
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-39655000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1833000
CY2023Q1	ttoo	Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrant Upon Public Offering Net StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantUponPublicOfferingNet	4031000
CY2023Q1	ttoo	Stock Issued During Period Value Issuance Of Common Stock Warrant Upon Cashless Exercises StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantUponCashlessExercises	938000
CY2023Q1	ttoo	Stock Issued During Period Value Issuance Of Common Stock Upon Pre Funded Warrant Exercises StockIssuedDuringPeriodValueIssuanceOfCommonStockUponPreFundedWarrantExercises	2000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17965000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-49886000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	913000
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18385000
CY2023Q2	ttoo	Stock Issued During Period Value Issuance Of Common Stock Warrant Upon Cashless Exercises StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantUponCashlessExercises	510000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6347000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-36423000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-28036000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1595000
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-13534000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-37773000
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	208000
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10000
CY2024Q2	ttoo	Stock Issued During Period Values Issuance Of Common Stock Pre Funded Warrants And Series A And Series B Common Stock Warrants From Private Placement Net StockIssuedDuringPeriodValuesIssuanceOfCommonStockPreFundedWarrantsAndSeriesAAndSeriesBCommonStockWarrantsFromPrivatePlacementNet	7269000
CY2024Q2	ttoo	Stock Issued During Period Values Issuance Of Common Stock To Related Party StockIssuedDuringPeriodValuesIssuanceOfCommonStockToRelatedParty	27963000
CY2024Q2	ttoo	Temporary Equity Stock Issued During Period Shares Value New Issues TemporaryEquityStockIssuedDuringPeriodSharesValueNewIssues	5388000
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-8963000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-5898000
	us-gaap	Profit Loss ProfitLoss	-22497000
	us-gaap	Profit Loss ProfitLoss	-24312000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	126000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	523000
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	739000
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	653000
	us-gaap	Share Based Compensation ShareBasedCompensation	1803000
	us-gaap	Share Based Compensation ShareBasedCompensation	2746000
	ttoo	Change In Fair Value Of Derivative Related To Term Loan With Related Party ChangeInFairValueOfDerivativeRelatedToTermLoanWithRelatedParty	1130000
	ttoo	Change In Fair Value Of Derivative Related To Term Loan With Related Party ChangeInFairValueOfDerivativeRelatedToTermLoanWithRelatedParty	252000
	ttoo	Change In Fair Value Of Derivative Warrant Liability ChangeInFairValueOfDerivativeWarrantLiability	-152000
	ttoo	Change In Fair Value Of Derivative Warrant Liability ChangeInFairValueOfDerivativeWarrantLiability	5888000
	ttoo	Issuance Costs Related To Common Stock Warrants IssuanceCostsRelatedToCommonStockWarrants	682000
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-21000
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-3000
	ttoo	Paid In Kind Interest Expense To Related Party PaidInKindInterestExpenseToRelatedParty	362000
	ttoo	Paid In Kind Interest Expense To Related Party PaidInKindInterestExpenseToRelatedParty	1050000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-123000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-814000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-974000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-574000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	350000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	374000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	159000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	938000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-629000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1936000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	105000
	ttoo	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-781000
	ttoo	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-653000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20924000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25327000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	153000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-153000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1000
	ttoo	Proceeds From Issuance Of Shares From Employee Stock Purchase Plan And Stock Option Exercises ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises	10000
	ttoo	Proceeds From Issuance Of Shares From Employee Stock Purchase Plan And Stock Option Exercises ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises	2000
	ttoo	Proceeds From Issuance Initial Public Offering Net Of Issuance Costs ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts	10918000
	ttoo	Proceeds From Issuance Initial Private Offering Net Of Issuance Costs ProceedsFromIssuanceInitialPrivateOfferingNetOfIssuanceCosts	7269000
	ttoo	Proceeds From Secondary Offering Net Of Issuance Costs ProceedsFromSecondaryOfferingNetOfIssuanceCosts	2203000
	ttoo	Proceeds From Secondary Offering Net Of Issuance Costs ProceedsFromSecondaryOfferingNetOfIssuanceCosts	19315000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9481000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30235000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11443000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4755000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16240000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11880000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4797000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16635000
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4246000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16084000
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	551000
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	551000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4797000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16635000
	us-gaap	Interest Paid Net InterestPaidNet	1677000
	us-gaap	Interest Paid Net InterestPaidNet	2005000
	ttoo	Transfer Of T2 Owned Instruments And Components To From Inventory TransferOfT2OwnedInstrumentsAndComponentsToFromInventory	-322000
	ttoo	Cashless Exercise Of Common Stock Warrants CashlessExerciseOfCommonStockWarrants	-1448000
	ttoo	Cancellation Of Term Loan In Exchange For Common Stock And Convertible Preferred Stock To Related Party CancellationOfTermLoanInExchangeForCommonStockAndConvertiblePreferredStockToRelatedParty	33353000
	ttoo	Wainwright Warrant Issued In Connection With Offering Costs Of May Two Thousand Twenty Four Private Offering WainwrightWarrantIssuedInConnectionWithOfferingCostsOfMayTwoThousandTwentyFourPrivateOffering	747000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	131000
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T2 Biosystems, Inc. and its subsidiary (the “Company,” “we,” or “T2”) have operations based in Lexington, Massachusetts. T2 Biosystems, Inc. was incorporated on April 27, 2006 as a Delaware corporation. The Company is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company has developed a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. The Company’s technology enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). We are currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. The Company’s current development efforts primarily target sepsis, bioterrorism and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had cash, cash equivalents, and restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">606.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, stockholders’ deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and has experienced cash outflows from operating activities since its inception. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through public equity and private debt financings, including the Company's August 2014 initial public offering, the December 2015 public offering, the September 2016 private investment in public equity (“PIPE”) financing, the September 2017 public offering, the June 2018 public offering, the July 2019 establishment of an equity distribution agreement and equity purchase agreement, the March 2021 establishment of an Equity Distribution Agreement (Note 9), the February 2023 public offering (Note 8), the May 2024 private offering (Note 8), private placements of redeemable convertible preferred stock and through debt financing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes its cash position is insufficient to fund future operations without financings by mid-third quarter 2024, which may include public or private equity or debt financings. These financings may not be successful, however, or on terms favorable to the Company or its stockholders, which would have a negative impact on the Company’s business, results of operations, financial condition and the Company’s ability to develop and commercialize its products and ultimately operate as a going concern.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the Company’s milestone-based product development contract with the Biomedical Advanced Research and Development Authority (“BARDA”) (Note 12) expired, which may impact the Company’s ability to continue to fund the development of its next-generation products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s T2Dx Instrument and T2Candida, T2Bacteria, and the T2Biothreat Panels are authorized for use in the United States by the U.S. Food and Drug Administration (“FDA”).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Accounting Standards Codification 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 205-40”), management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that its cash, cash equivalents, and restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 will not be sufficient to fund its current operating plan for at least one year from issuance of these financial statements, as certain elements of its operating plan cannot be considered probable. Absent any reductions in current operating expenses, the Company believes it will require additional financing by mid-third quarter of 2024, which may include public or private equity or debt financings. Under ASC 205-40, the future receipt of potential funding from co-development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company’s control.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's Term Loan Agreement (the “Term Loan Agreement”) with certain entities managed by CR Group L.P., a Delaware limited partnership (each entity, a “CRG entity” and collectively, “CRG”) (Note 6) has a minimum liquidity covenant, which initially required the Company to maintain a minimum cash balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In May 2023, CRG reduced the minimum liquidity covenant under the Term Loan Agreement from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> until December 31, 2023. In July 2023, April 2024, and May 2024, the Company converted $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of the outstanding debt principal with CRG to equity. In October 2023, the Term Loan Agreement was amended to extend both the interest-only period and the maturity date by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 30, 2024 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and permanently reduce the minimum liquidity covenant from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. There can be no assurances that the Company will continue to be in compliance with the cash covenant in future periods without additional funding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 30, 2023, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 555(a)(2) (the “Minimum Bid Price Rule”). On May 23, 2023, Nasdaq notified the Company that its securities were subject to delisting due to non-compliance with the Minimum Bid Price Rule and to maintain a minimum value of listed securities (the “MVLS Rule”) of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company requested a hearing with Nasdaq and, on July 6, 2023, appealed to the Nasdaq Hearings Panel for an extension to the time period in which to regain compliance with the MVLS Rule and the Minimum Bid Price Rule. On July 26, 2023, we filed a definitive proxy statement to effect a reverse stock split of our common stock in connection with our annual meeting that occurred in September 2023 as required by the Nasdaq Hearings Panel. On August 9, 2023, the Company received written notice from Nasdaq informing the Company that it had regained compliance with the MVLS Rule. On September 15, 2023, at the Company’s annual meeting of stockholders, the Company’s stockholders approved an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock. On October 12, 2023, the Company announced that its board of directors had approved the reverse stock split at the ratio of 1 post-split share for every </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-split shares, which was effective as of October 12, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2023, the Company received written notice from Nasdaq informing the Company that it has regained compliance with the Minimum Bid Price Rule. The Company will be subject to a Mandatory Panel Monitor for a period of one year. If, within that one-year monitoring period, the Company fails to comply with the Minimum Bid Price Rule, the Company will not be permitted additional time to regain compliance with the Minimum Bid Price Rule. However, the Company will have an opportunity to request a new hearing with the Nasdaq Listing Qualifications Hearing Panel prior to the Company’s securities being delisted from Nasdaq.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 20, 2023, the Company received written notice from Nasdaq informing the Company that it no longer satisfied the MVLS Rule. In accordance with the terms of the Mandatory Panel Monitor, the Company was not granted a grace period but rather issued a delist determination, which will be stayed if the Company exercises its right to appeal by requesting a hearing and paying a non-refundable $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fee. The Company paid the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> applicable fee and requested a new hearing, which will stay any further action by Nasdaq at least pending the issuance of its decision and the expiration of any extension that may be granted to the Company as a result of the hearing. The Company’s common stock will remain listed and eligible to trade on Nasdaq pending the outcome of the hearing. On February 15, 2024, the Company appealed to the Nasdaq Hearings Panel for an extension to the time period in which to regain compliance with the MVLS Rule. On March 11, 2024, the Company received notice from the Nasdaq Hearings Panel that it had granted the Company’s request for continued listing on Nasdaq, subject to the Company demonstrating compliance with Nasdaq’s MVLS Rule on or before May 20, 2024. On May 21, 2024, the Company received written notice from Nasdaq informing the Company that it has regained compliance with the MVLS Rule for continued listing on the Nasdaq Capital Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, delaying certain research projects and capital expenditures, and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date these audited consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or maintain reduced expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</span></p>
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4800000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-606800000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-5900000
CY2024Q2	ttoo	Cash Cash Equivalents Marketable Securities And Restricted Cash CashCashEquivalentsMarketableSecuritiesAndRestrictedCash	4800000
CY2023Q1	ttoo	Maximum Bidding Price Stock For Last Thirty Consecutive Business Days MaximumBiddingPriceStockForLastThirtyConsecutiveBusinessDays	1
CY2023Q2	ttoo	Minimum Market Value Of Listed Securities MinimumMarketValueOfListedSecurities	35000000
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1
CY2023Q4	ttoo	Payment For Legal Hearing Fee PaymentForLegalHearingFee	20000
CY2023Q4	ttoo	Payment For Legal Hearing Fee PaymentForLegalHearingFee	20000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Guarantees</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such a capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. See Note 14 for a discussion about the Billerica, Massachusetts lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></p>
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1952000
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1964000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4013000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4042000
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	100000
	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation	The Company expects to recognize 44% of this amount as revenue within one year and the remainder within three years.
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.44
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	300000
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	300000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	300000
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1400000
CY2024Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	1300000
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2200000
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	1300000
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	400000
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1600000
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1554000
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1662000
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	424000
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2146000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1881000
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1871000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1441000
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1152000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1497000
CY2024Q2	us-gaap	Inventory Net InventoryNet	5169000
CY2023Q4	us-gaap	Inventory Net InventoryNet	4819000
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16461000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16509000
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14944000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14851000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1517000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1658000
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2594000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2705000
CY2024Q2	ttoo	Accrued Clinical Trial And Development Expenses AccruedClinicalTrialAndDevelopmentExpenses	382000
CY2023Q4	ttoo	Accrued Clinical Trial And Development Expenses AccruedClinicalTrialAndDevelopmentExpenses	285000
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	496000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	554000
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	389000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	839000
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	415000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	522000
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4276000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4905000
CY2024Q2	ttoo	Debt Instrument Carrying Amount Including Paid In Kind Interest Before Unamortized Discount And Issuance Costs DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts	12610000
CY2023Q4	ttoo	Debt Instrument Carrying Amount Including Paid In Kind Interest Before Unamortized Discount And Issuance Costs DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts	44457000
CY2024Q2	ttoo	Debt Instrument Unaccrued Paid In Kind Interest DebtInstrumentUnaccruedPaidInKindInterest	653000
CY2023Q4	ttoo	Debt Instrument Unaccrued Paid In Kind Interest DebtInstrumentUnaccruedPaidInKindInterest	3037000
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	170000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	136000
CY2024Q2	us-gaap	Notes Payable NotesPayable	11787000
CY2023Q4	us-gaap	Notes Payable NotesPayable	41284000
CY2023Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	90185
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	12000000
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1100000
CY2024Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1700000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	8000000
CY2024Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	ttoo	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	200000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	500000
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	196000
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	907000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1791000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2740000
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4553011
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4553011
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	74833
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	74833
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-24-094135-index-headers.html	Edgar Link	pending
0000950170-24-094135-index.html	Edgar Link	pending
0000950170-24-094135.txt	Edgar Link	pending
0000950170-24-094135-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ttoo-20240630.htm	Edgar Link	pending
ttoo-20240630.xsd	Edgar Link	pending
ttoo-ex31_1.htm	Edgar Link	pending
ttoo-ex31_2.htm	Edgar Link	pending
ttoo-ex32_1.htm	Edgar Link	pending
ttoo-ex32_2.htm	Edgar Link	pending
ttoo-20240630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TTOO
T2 Biosystems, Inc. Stock $ttoo

2024 Q3 Form 10-Q Financial Statement

#000095017024094135 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTOO T2 Biosystems, Inc. Stock $ttoo

2024 Q3 Form 10-Q Financial Statement

#000095017024094135 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTOO
T2 Biosystems, Inc. Stock $ttoo